Aligos Therapeutics (ALGS) Common Equity (2019 - 2026)

Aligos Therapeutics (ALGS) has reported Common Equity for 8 consecutive years, with $31.9 million the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Common Equity fell 68.7% year-over-year to $31.9 million; the trailing twelve-month figure through Jun 2026 stood at $31.9 million (down 68.7% YoY), and the FY2025 full-year result was $53.5 million, up 284.81% from the prior year.
• Common Equity was little changed at $31.9 million in Q2 2026 per ALGS's latest filing, from $31.8 million in the prior quarter.
• Across five years, Common Equity topped out at $152.9 million in Q1 2022 and bottomed at -$29.0 million in Q4 2024.
• Historically, Common Equity has averaged $76.3 million across 5 years, with a median of $70.7 million in 2023.
• The sharpest annual moves came in 2024 and 2025: Common Equity plunged 131.47% in 2024, then soared 284.81% in 2025.
• Over 5 years, Common Equity stood at $103.9 million in 2022, then decreased by 11.38% to $92.1 million in 2023, then slumped by 131.47% to -$29.0 million in 2024, then jumped by 284.81% to $53.5 million in 2025, then slumped by 40.45% to $31.9 million in 2026.
• According to Business Quant data, Common Equity over the past three periods registered $31.9 million, $31.8 million, and $53.5 million for Q2 2026, Q1 2026, and Q4 2025 respectively.